Here are four things to know:
1. Dr. Manax Rutson most recently served as executive medical director and gastrointestinal therapeutic lead for U.S. medical affairs at Celgene.
2. In her new role, Dr. Manax Rutson will work closely with the organization’s chief research officer, clinical cancer research institutions and biopharmaceutical companies.
3. She will also have operational oversight over the organization’s high-priority clinical initiatives, including the Precision Promise initiative and its Clinical Trial Consortium.
4. Precision Promise is a clinical trial that aims to further the organization’s goal of doubling pancreatic cancer survival by 2020. The initiative will include 12 initial Clinical Trial Consortium sites that will provide treatment to pancreatic cancer patients.
More articles on executive moves:
Baylor Scott & White Health taps James Hinton to lead as CEO: 5 takeaways
Estes Park Medical Center names Larry Leaming CEO: 4 key notes
Fauquier Health CEO Roger Baker announces retirement plans